Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22446555 | 1.00 | KLK7 (0.45) | KLK7FKBP1AKLK5FOLH1PRSS1 | |
| SCHEMBL30387086 | 1.00 | KLK7 (0.45) | KLK7FKBP1AKLK5FOLH1PRSS1 | |
| SCHEMBL12643706 | 1.00 | KLK7 (0.45) | KLK7FKBP1AKLK5FOLH1PRSS1 | |
| SCHEMBL14265386 | 0.94 | CASP1 (0.42) | KLK7FKBP1AKLK5FOLH1PRSS1 | |
| SCHEMBL31486301 | 0.91 | FKBP1A (0.44) | KLK7FKBP1AKLK5PRSS1PRSS2 | |
| SCHEMBL8667026 | 0.91 | KLK7 (0.48) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL30387509 | 0.90 | FKBP1A (0.39) | KLK7FKBP1AFOLH1CTSL | |
| SCHEMBL30387573 | 0.90 | CASP1 (0.42) | KLK7FKBP1AKLK5CTSL | |
| SCHEMBL30387038 | 0.90 | CASP1 (0.42) | KLK7FKBP1ACTSL | |
| SCHEMBL23121510 | 0.89 | FKBP1A (0.42) | KLK7FKBP1AKLK5FOLH1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | KLK7 170/4885FKBP1A 4076/4885KLK5 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.